A citation-based method for searching scientific literature


List of co-cited articles
148 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine,[...]. Alzheimers Dement 2011
43

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.
J Scott Roberts, Laura B Dunn, Gil D Rabinovici. Neurodegener Dis Manag 2013
32
33

The A4 study: stopping AD before symptoms begin?
Reisa A Sperling, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, Paul Aisen. Sci Transl Med 2014
441
30


Disclosure of APOE genotype for risk of Alzheimer's disease.
Robert C Green, J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Tamsen Brown, Susan LaRusse Eckert, Melissa Butson, A Dessa Sadovnick, Kimberly A Quaid,[...]. N Engl J Med 2009
320
26

Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
Scott Y H Kim, Jason Karlawish, Benjamin E Berkman. Neurology 2015
29
27

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish. Alzheimers Res Ther 2015
52
26

Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults.
Tara T Lineweaver, Mark W Bondi, Douglas Galasko, David P Salmon. Am J Psychiatry 2014
62
20

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Yen Ying Lim, Paul Maruff, Christine Getter, Peter J Snyder. Alzheimers Dement 2016
37
20

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois, Harald Hampel, Howard H Feldman, Philip Scheltens, Paul Aisen, Sandrine Andrieu, Hovagim Bakardjian, Habib Benali, Lars Bertram, Kaj Blennow,[...]. Alzheimers Dement 2016
745
20

Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Jeffrey L Cummings, Steven T Dekosky, Pascale Barberger-Gateau, André Delacourte, Giovanni Frisoni, Nick C Fox, Douglas Galasko,[...]. Lancet Neurol 2010
16

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
Serena Chao, J Scott Roberts, Theresa M Marteau, Rebecca Silliman, L Adrienne Cupples, Robert C Green. Alzheimer Dis Assoc Disord 2008
164
16

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Guy M McKhann, David S Knopman, Howard Chertkow, Bradley T Hyman, Clifford R Jack, Claudia H Kawas, William E Klunk, Walter J Koroshetz, Jennifer J Manly, Richard Mayeux,[...]. Alzheimers Dement 2011
16

Disclosure of amyloid imaging results to research participants: has the time come?
Jennifer H Lingler, William E Klunk. Alzheimers Dement 2013
29
17

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. Alzheimers Dement 2013
292
16

Should we disclose amyloid imaging results to cognitively normal individuals?
Joshua D Grill, David K Johnson, Jeffrey M Burns. Neurodegener Dis Manag 2013
24
20

Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
S Gauthier, A Leuzy, E Racine, P Rosa-Neto. Prog Neurobiol 2013
51
16

Safety of disclosing amyloid status in cognitively normal older adults.
Jeffrey M Burns, David K Johnson, Edward P Liebmann, Rebecca J Bothwell, Jill K Morris, Eric D Vidoni. Alzheimers Dement 2017
38
16

Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment.
Joshua D Grill, Jason Karlawish, David Elashoff, Barbara G Vickrey. Alzheimers Dement 2013
25
16

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Harald Hampel, José Luis Molinuevo, Kaj Blennow, Steven T DeKosky, Serge Gauthier, Dennis Selkoe, Randall Bateman,[...]. Lancet Neurol 2014
13

Effect of Alzheimer disease genetic risk disclosure on dietary supplement use.
Jacqueline A Vernarelli, J Scott Roberts, Susan Hiraki, Clara A Chen, L Adrienne Cupples, Robert C Green. Am J Clin Nutr 2010
48
13

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Steven T Dekosky, Pascale Barberger-Gateau, Jeffrey Cummings, André Delacourte, Douglas Galasko, Serge Gauthier, Gregory Jicha,[...]. Lancet Neurol 2007
13


The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Marilyn S Albert, Steven T DeKosky, Dennis Dickson, Bruno Dubois, Howard H Feldman, Nick C Fox, Anthony Gamst, David M Holtzman, William J Jagust, Ronald C Petersen,[...]. Alzheimers Dement 2011
13

Public perceptions of presymptomatic testing for Alzheimer disease.
Richard J Caselli, Jessica Langbaum, Gary E Marchant, Rachel A Lindor, Katherine S Hunt, Bruce R Henslin, Amylou C Dueck, Jason S Robert. Mayo Clin Proc 2014
33
13

Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.
Cathleen D Zick, Charles J Mathews, J Scott Roberts, Robert Cook-Deegan, Robert J Pokorski, Robert C Green. Health Aff (Millwood) 2005
78
13

Making sense of nonsense: experiences of mild cognitive impairment.
Renée L Beard, Tara M Neary. Sociol Health Illn 2013
55
13

The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment.
Rebecca Johnson, Kristin Harkins, Mark Cary, Pamela Sankar, Jason Karlawish. Soc Sci Med 2015
37
13

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Jessica Mozersky, Pamela Sankar, Kristin Harkins, Sara Hachey, Jason Karlawish. JAMA Neurol 2018
32
13

Patient and caregiver reactions to clinical amyloid imaging.
Joshua D Grill, Chelsea G Cox, Sarah Kremen, Mario F Mendez, Edmond Teng, Jill Shapira, John M Ringman, Liana G Apostolova. Alzheimers Dement 2017
19
21

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.
José L Molinuevo, Jordi Cami, Xavier Carné, Maria C Carrillo, Jean Georges, Maria B Isaac, Zaven Khachaturian, Scott Y H Kim, John C Morris, Florence Pasquier,[...]. Alzheimers Dement 2016
28
14

A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.
Jane S Paulsen, Martha Nance, Ji-In Kim, Noelle E Carlozzi, Peter K Panegyres, Cheryl Erwin, Anita Goh, Elizabeth McCusker, Janet K Williams. Prog Neurobiol 2013
78
13

Genetic testing for Alzheimer's and long-term care insurance.
Donald H Taylor, Robert M Cook-Deegan, Susan Hiraki, J Scott Roberts, Dan G Blazer, Robert C Green. Health Aff (Millwood) 2010
37
10

Preclinical Alzheimer disease-the challenges ahead.
Reisa A Sperling, Jason Karlawish, Keith A Johnson. Nat Rev Neurol 2013
164
10

What makes clinical research ethical?
E J Emanuel, D Wendler, C Grady. JAMA 2000
10


Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk.
Holly C Gooding, Erin L Linnenbringer, Jeffrey Burack, J Scott Roberts, Robert C Green, Barbara B Biesecker. Patient Educ Couns 2006
44
10

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
Randall J Bateman, Chengjie Xiong, Tammie L S Benzinger, Anne M Fagan, Alison Goate, Nick C Fox, Daniel S Marcus, Nigel J Cairns, Xianyun Xie, Tyler M Blazey,[...]. N Engl J Med 2012
10

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Victor L Villemagne, Samantha Burnham, Pierrick Bourgeat, Belinda Brown, Kathryn A Ellis, Olivier Salvado, Cassandra Szoeke, S Lance Macaulay, Ralph Martins, Paul Maruff,[...]. Lancet Neurol 2013
10

Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project.
Craig W Ritchie, José Luis Molinuevo, Luc Truyen, Andrew Satlin, Serge Van der Geyten, Simon Lovestone. Lancet Psychiatry 2016
124
10

Making sense of mild cognitive impairment: a qualitative exploration of the patient's experience.
Jennifer Hagerty Lingler, Marcie C Nightingale, Judith A Erlen, April L Kane, Charles F Reynolds, Richard Schulz, Steven T DeKosky. Gerontologist 2006
71
10

Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment.
Brian D Carpenter, Chengjie Xiong, Emily K Porensky, Monica M Lee, Patrick J Brown, Mary Coats, David Johnson, John C Morris. J Am Geriatr Soc 2008
100
10

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
Tiia Ngandu, Jenni Lehtisalo, Alina Solomon, Esko Levälahti, Satu Ahtiluoto, Riitta Antikainen, Lars Bäckman, Tuomo Hänninen, Antti Jula, Tiina Laatikainen,[...]. Lancet 2015
10

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure.
B R Ott, M A Pelosi, G Tremont, P J Snyder. Alzheimers Dement (N Y) 2016
16
18

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.
Jonathan Gooblar, Catherine M Roe, Natalie J Selsor, Matthew J Gabel, John C Morris. JAMA Neurol 2015
23
13

Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
Joshua D Grill, Yan Zhou, David Elashoff, Jason Karlawish. Neurobiol Aging 2016
22
13

Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study.
Meera Sheffrin, Irena Stijacic Cenzer, Michael A Steinman. Alzheimers Res Ther 2016
12
25

Reexamining the relationships among dementia, stigma, and aging in immigrant Chinese and Vietnamese family caregivers.
Dandan Liu, Ladson Hinton, Cindy Tran, Devon Hinton, Judith C Barker. J Cross Cult Gerontol 2008
87
10

Diagnostic labels, stigma, and participation in research related to dementia and mild cognitive impairment.
Linda Garand, Jennifer H Lingler, Kyaien O Conner, Mary Amanda Dew. Res Gerontol Nurs 2009
70
10

Communicating mild cognitive impairment diagnoses with and without amyloid imaging.
Joshua D Grill, Liana G Apostolova, Szofia Bullain, Jeffrey M Burns, Chelsea G Cox, Malcolm Dick, Dean Hartley, Claudia Kawas, Sarah Kremen, Jennifer Lingler,[...]. Alzheimers Res Ther 2017
30
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.